SEC Filing Summary: Second Sight Medical Products, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on February 14, 2020, reporting events occurring on February 12, 2020. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements. Note: The input metadata references "Vivani Medical, Inc.," but the filing text explicitly identifies the registrant as Second Sight Medical Products, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments approved by the Compensation Committee based on 2019 performance.
Material Changes and Executive Compensation
On February 12, 2020, the Compensation Committee approved salary adjustments, bonuses, and long-term stock option awards for three executive officers based on 2019 performance milestones:
- Jonathan Will McGuire (President and CEO): Salary increased from $426,140 to $441,055; awarded 43,755 stock options and a $193,361 bonus.
- William Patrick Ryan (Chief Operating Officer): Salary increased from $313,080 to $324,038; awarded 28,305 stock options and a $90,400 bonus.
- John T. Blake (Chief Financial Officer): Salary increased from $306,870 to $317,610; awarded 20,147 stock options and an $88,610 bonus.
Stock options have a strike price of $5.98 per share (closing price on grant date), a 10-year term, and vest over four years in equal monthly installments contingent upon continuous employment.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies. The text is limited to the disclosure of the specific compensatory arrangements approved.
Key Facts for Investor Verification
- Verify the total cash bonus payout of approximately $372,371 to the three named executives.
- Confirm the total number of stock options granted (92,207 shares) and the associated dilution impact.
- Review the vesting schedule to understand the retention timeline for key management.
- Check the company's cash position to assess the ability to fund the immediate bonus payments.
- Clarify the discrepancy between the metadata company name (Vivani Medical) and the filing registrant (Second Sight Medical Products).